Yondelis and Transaminases increased - a phase IV clinical study of FDA data

Summary:

Transaminases increased is reported as a side effect among people who take Yondelis (trabectedin), especially for people who are male, 30-39 old, have been taking the drug for 6 - 12 months also take Gemcitabine, and have Ewing's sarcoma.

The phase IV clinical study analyzes which people have Transaminases increased when taking Yondelis. It is created by eHealthMe based on reports of 1,220 people who have side effects when taking Yondelis from the FDA, and is updated regularly.

What is Yondelis?

Yondelis has active ingredients of trabectedin. eHealthMe is studying from 1,220 Yondelis users. Check the latest studies of Yondelis.

What is Transaminases increased?

Transaminases increased is found to be associated with 1,155 drugs and 1,514 conditions by eHealthMe. Check the latest studies of Transaminases increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

1,220 people reported to have side effects when taking Yondelis.
Among them, 36 people (2.95%) have Transaminases increased.

Could Yondelis cause Transaminases increased?

Among these 36 people:

How long have people been on Yondelis when they have Transaminases increased? *

What is the gender of people who have Transaminases increased when taking Yondelis? *

female: 37.14 %
male: 62.86 %

What is the age of people who have Transaminases increased when taking Yondelis? *

What are other drugs people take besides Yondelis? *

What are other side effects people have besides Transaminases increased? *

Haematotoxicity (toxins that destroy red blood cells): 21 people, 58.33%
Diarrhea: 20 people, 55.56%
Hepatotoxicity (chemical-driven liver damage): 16 people, 44.44%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 15 people, 41.67%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 6 people, 16.67%
Death: 6 people, 16.67%
Weakness: 6 people, 16.67%
Thrombocytopenia (decrease of platelets in blood): 5 people, 13.89%
Fever: 4 people, 11.11%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 4 people, 11.11%

What are the existing conditions these people have? *

Ewing's Sarcoma (malignant small, round, blue cell tumour): 14 people, 38.89%
Ovarian Cancer (cancer of ovary): 7 people, 19.44%
Synovial Sarcoma (tumour of synovial membrane of joint): 4 people, 11.11%
Liposarcoma Metastatic (a cancer tumour that arises in fat cells in deep soft tissue spreads to other part): 2 people, 5.56%
Metastases To Liver (cancer spreads to liver): 2 people, 5.56%
Breast Cancer: 2 people, 5.56%
Constipation: 2 people, 5.56%
Ewing's Sarcoma Recurrent (malignant small, round, blue cell tumour- recurrent): 2 people, 5.56%
Infection: 2 people, 5.56%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Yondelis and have Transaminases increased?

- Check whether Transaminases increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yondelis:

Yondelis (1,220 reports)

Browse all side effects of Yondelis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transaminases increased:

Transaminases increased (1,155 drugs)

Browse all the conditions that are associated with Transaminases increased:

Transaminases increased (1,514 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on trabectedin (the active ingredients of Yondelis) and Yondelis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.